City Therapeutics raised $99.5 million in a Series B financing to expand development of three RNAi candidates and to broaden beyond initial liver-focused targets. The startup—built by former Alnylam executives—said the capital will support clinical development and additional target discovery as it continues building an RNAi pipeline intended to compete on efficacy, dosing convenience, and differentiation across indications. The funding highlights sustained investor appetite for next-generation RNAi approaches, particularly as RNA delivery and durability performance remain central gating factors for clinical success. Key takeaway: City is using Series B scale-up to accelerate early human evidence generation across multiple RNAi programs.